Skip to main content Accesibility Help
×
×
Home

Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom

  • R. G. PEBODY (a1), N. ANDREWS (a1), D. M. FLEMING (a2), J. McMENAMIN (a3), S. COTTRELL (a4), B. SMYTH (a5), H. DURNALL (a2), C. ROBERTSON (a3) (a6) (a7), W. CARMAN (a8), J. ELLIS (a9), P. SEBASTIAN-PILLAI (a9), M. ZAMBON (a9), C. KEARNS (a5), C. MOORE (a4), D. RH. THOMAS (a4) and J. M. WATSON (a1)...
Summary

An analysis was undertaken to measure age-specific vaccine effectiveness (VE) of 2010/11 trivalent seasonal influenza vaccine (TIV) and monovalent 2009 pandemic influenza vaccine (PIV) administered in 2009/2010. The test-negative case-control study design was employed based on patients consulting primary care. Overall TIV effectiveness, adjusted for age and month, against confirmed influenza A(H1N1)pdm 2009 infection was 56% (95% CI 42–66); age-specific adjusted VE was 87% (95% CI 45–97) in <5-year-olds and 84% (95% CI 27–97) in 5- to 14-year-olds. Adjusted VE for PIV was only 28% (95% CI −6 to 51) overall and 72% (95% CI 15–91) in <5-year-olds. For confirmed influenza B infection, TIV effectiveness was 57% (95% CI 42–68) and in 5- to 14-year-olds 75% (95% CI 32–91). TIV provided moderate protection against the main circulating strains in 2010/2011, with higher protection in children. PIV administered during the previous season provided residual protection after 1 year, particularly in the <5 years age group.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom
      Available formats
      ×
Copyright
Corresponding author
*Author for correspondence: Dr R. G. Pebody, Health Protection Services – Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK. (Email: Richard.Pebody@hpa.org.uk)
References
Hide All
1.Wichmann, O, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Eurosurveillance 2010; 15.
2.Valenciano, M, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Medicine 2011; 8: e1000388.
3.Hardelid, P, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009–2010. Eurosurveillance 2011; 16.
4.Andrews, N, et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. Journal of Infectious Diseases 2011; 203: 3239.
5.Pebody, R, et al. Effectiveness of seasonal 2010/11 and pandemic influenza A(H1N1)2009 vaccines in preventing influenza infection in the United Kingdom: mid-season analysis 2010/11. Eurosurveillance 2011; 16.
6.Jimenez-Jorge, S, et al. Effectiveness of the 2010–11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012; 30: 35953602.
7.Department of Health Seasonal influenza vaccine uptake amongst GP patient groups in England, 2010/11 (http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_129856.pdf).
8.Skowronski, DM, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25: 28422851.
9.Fleming, DM, et al. Estimating Influenza vaccine effectiveness using routinely collected laboratory data. Journal of Epidemiology and Community Health 2010; 64: 10621067.
10.Ellis, J, et al. Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Eurosurveillance 2009; 14: pii = 19230.
11.Gunson, R, et al. Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus. Journal of Virological Methods 2010; 163: 258261.
12.van Buuren, S, Groothuis-Oudshoorn, K. mice: multivariate imputation by chained equations. Journal of Statistical Software 2011; 45: 167.
13.Ferdinands, JM, et al. Influenza vaccination status is not associated with influenza testing among children: implications for observational studies of vaccine effectiveness. Vaccine 2011; 29: 19351940.
14.Orenstein, EW, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology 2007; 36: 623631.
15.Kissling, E, Valenciano, M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Eurosurveillance 2011; 16.
16.Fielding, JE, et al. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerging Infectious Diseases 2011; 17: 11811187.
17.Castilla, J, et al. Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. Eurosurveillance 2011; 16.
18.Skowronski, DM, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010–11 season. Clinical Infectious Diseases. Published online: 21 May 2012. PMID no.: 22539661.
19.Szilagyi, PG, et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Archives of Pediatrics & Adolescent Medicine 2008; 162: 943951.
20.Heinonen, S, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infectious Diseases 2011; 11: 2329.
21.Eisenberg, KW, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003–2004 and 2004–2005 influenza seasons. Pediatrics 2008; 122: 911919.
22.Griffin, MR, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011; 6: e23085.
23.Walker, WT, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clinical Infectious Diseases 2012; 54: 661669.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed